Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its earnings results on Friday. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.40), Briefing.com reports. During the same quarter last year, the company earned ($1.85) EPS.

Zentalis Pharmaceuticals Trading Down 9.4 %

Shares of ZNTL opened at $3.00 on Friday. The firm’s fifty day simple moving average is $5.39 and its two-hundred day simple moving average is $10.38. Zentalis Pharmaceuticals has a 12 month low of $2.96 and a 12 month high of $29.03. The stock has a market capitalization of $213.08 million, a P/E ratio of -0.90 and a beta of 1.70.

Insider Buying and Selling

In other news, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wedbush lowered shares of Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $15.00 to $4.00 in a research note on Tuesday, June 18th. Stifel Nicolaus dropped their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. Wells Fargo & Company downgraded Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $29.00 to $9.00 in a research note on Tuesday, June 18th. Oppenheimer dropped their price target on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 18th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $8.00 price objective (down from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $11.33.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.